Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences, Inc. (Nasdaq: PLSE) generates frequent news as it advances its proprietary nPulse nanosecond pulsed field ablation (nsPFA) technology across cardiac and soft tissue applications. The company’s updates focus on clinical trial progress, regulatory milestones, scientific data presentations and early commercial activity for its nsPFA-based systems.
Investors and clinicians following PLSE news will see announcements on key atrial fibrillation programs, including the nPulse Cardiac Surgical System and the nPulse Cardiac Catheter Ablation System. Company releases describe IDE approvals from the U.S. Food and Drug Administration, enrollment of patients in the NANOCLAMP AF and NANOPULSE-AF studies, and feasibility results from European centers using surgical and catheter-based nsPFA devices. Late-breaking data presentations at major cardiology and cardiothoracic surgery meetings are also highlighted.
News flow also covers soft tissue ablation initiatives, such as the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules and research collaborations with academic centers on benign and malignant thyroid tumors. Pulse Biosciences reports publication of first-in-human thyroid data, IDE approvals for thyroid studies, and progress in multi-center trials like PRECISE-BTN.
In addition, PLSE news includes quarterly business updates and financial results, inducement equity grants under Nasdaq rules, and participation in healthcare investor conferences. These items provide context on the company’s operating plans, clinical strategy and capital markets activity. For readers tracking the development of nsPFA technology in atrial fibrillation and thyroid or other soft tissue indications, the Pulse Biosciences news page offers a consolidated view of company disclosures, clinical milestones and corporate events over time.
Pulse Biosciences (Nasdaq: PLSE) announced that its Compensation Committee approved inducement equity awards to two new employees on December 15, 2025 under the 2017 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards grant options to purchase an aggregate of 3,400 shares at an exercise price of $14.13 per share (equal to the closing price on December 15, 2025). Options vest on a four-year, time-based schedule with 1/4 vesting annually, subject to continued employment, and are governed by the inducement plan and award agreements.
Pulse Biosciences (Nasdaq: PLSE) announced the U.S. Food and Drug Administration has granted an IDE to start the NANOPULSE-AF study evaluating its nPulse Cardiac Catheter Ablation System for treatment of paroxysmal atrial fibrillation.
The single-arm, multicenter, prospective study plans up to 30 sites (including three outside the U.S.) and up to 145 patients (ClinicalTrials.gov NCT07018596). Pulse noted an ongoing European feasibility study has enrolled 150 patients with follow-up ongoing. The nPulse system uses nanosecond pulsed field ablation (nsPFA) and is designed to deliver a complete circumferential lesion in a single brief application, aiming to lower total energy and reduce collateral injury.
Pulse Biosciences (Nasdaq: PLSE) announced a research collaboration with MD Anderson to study its nPulse™ Vybrance™ Percutaneous Electrode System for benign and malignant thyroid tumors.
An FDA Investigational Device Exemption (IDE) for a first-in-human feasibility study was approved. The two-site trial is planned to begin early 2026 and enroll 30 subjects to evaluate safety and effectiveness for papillary thyroid microcarcinoma. Preclinical work with MD Anderson on anaplastic thyroid carcinoma is ongoing.
Pulse Biosciences (Nasdaq: PLSE) announced inducement equity awards approved November 18, 2025 under its 2017 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The Compensation Committee granted options to three new employees to purchase an aggregate of 13,450 shares of common stock.
The options carry an exercise price of $13.58 per share (equal to the closing price on November 18, 2025) and vest on a time-based four-year schedule with 1/4 vesting annually, subject to continued employment and the award agreements.
Pulse Biosciences (Nasdaq: PLSE) will present at two investor conferences in New York in November–December 2025. Management is scheduled to speak at the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 at 2:40 PM ET and at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 9:50 AM ET. Live and recorded webcasts will be available on the company investor website at http://investors.pulsebiosciences.com/.
Pulse Biosciences (Nasdaq: PLSE) reported Q3 2025 business updates and financial results for the quarter ended September 30, 2025. Key clinical milestones include FDA IDE approval and initial enrollment in the nPulse Cardiac Surgery System surgical AF study (NANOCLAMP AF), PRECISE-BTN study 40% enrolled for benign thyroid nodules, and submission/planned IDE start for the endocardial nPulse 360° catheter in Q1 2026. The company has treated over 200 patients across programs and generated $86 thousand revenue from limited market release.
Q3 GAAP costs and expenses were $20.5M (GAAP net loss $19.4M); non-GAAP loss was $13.5M. Cash and equivalents were $95.2M at September 30, 2025.
Pulse Biosciences (Nasdaq: PLSE) announced first U.S. patient enrollment in the NANOCLAMP AF Study on October 24, 2025, using the nPulse Cardiac Surgical System after receiving FDA IDE approval.
The single-arm, prospective multicenter study will evaluate safety and effectiveness of the nsPFA-driven nPulse Cardiac Clamp for atrial fibrillation during concomitant surgical procedures, with multiple U.S. and two international sites planned. The device holds FDA Breakthrough Device designation (July 2024) and is in the FDA TPLC Advisory Program.
Pulse Biosciences (Nasdaq: PLSE) will report third quarter 2025 business updates and financial results after market close on Wednesday, November 5, 2025.
Company management will host a conference call on November 5, 2025 at 1:30 PM PT / 4:30 PM ET. U.S. dial-in is 1-800-715-9871; international dial-in is 1-646-307-1963; use Conference ID 7706791. A live and recorded webcast will be available on the Pulse Biosciences investors website at http://investors.pulsebiosciences.com/.
Pulse Biosciences (Nasdaq: PLSE) announced that its Compensation Committee granted inducement equity awards to three new employees on October 14, 2025 under the company’s 2017 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards total up to 8,550 options to purchase common stock at an exercise price of $17.26 per share (equal to the October 14, 2025 closing price). Options vest over four years with 1/4 vesting annually and are subject to the plan and individual award agreements.
Pulse Biosciences (Nasdaq: PLSE) reported late-breaking first-in-human feasibility results for the nPulse™ Cardiac Surgical System presented at EACTS on October 10, 2025. The study has treated 44 patients, with electroanatomical mapping at ~3 months in 24 patients. Key outcomes in the initial cohort include 100% posterior box isolation (high-dose cohort), 94% pulmonary vein isolation per vein (63/67) at ~3 months, an average total ablation time of 50 seconds with ~13 applications, and no reports of esophageal or phrenic nerve injury or ablation-related severe/major adverse events. The company plans to initiate an IDE study later in 2025 to further validate the system for AF surgical ablation.